SLN logo

SLN
Silence Therapeutics Plc - ADR

448
Mkt Cap
$292.85M
Volume
102,638.00
52W High
$8.40
52W Low
$4.19
PE Ratio
-3.89
SLN Fundamentals
Price
$6.58
Prev Close
$6.20
Open
$6.38
50D MA
$6.58
Beta
0.79
Avg. Volume
429,635.06
EPS (Annual)
-$1.88
P/B
5.93
Rev/Employee
$6,367.11
$202.21
Loading...
Loading...
News
all
press releases
Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference
Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Curtis Rambaran, MD, Chief Medical Officer of Silence Therapeutics, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor...
News Placeholder
More News
News Placeholder
Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results
Silence Therapeutics plc, Nasdaq: SLN (Silence or the Company), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the...
News Placeholder
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Short Interest Up 13.3% in April
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN - Get Free Report) was the recipient of a large increase in short interest in April. As of April 15th, there was short interest totaling 2,075,273...
News Placeholder
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Given Average Rating of "Moderate Buy" by Brokerages
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the seven ratings firms that are presently covering the stock...
News Placeholder
Silence Therapeutics (NASDAQ:SLN) Shares Down 1.8% - Here's What Happened
Silence Therapeutics (NASDAQ:SLN) Trading Down 1.8% - Here's Why...
News Placeholder
Silence Therapeutics (SLN) Soars 19.0%: Is Further Upside Left in the Stock?
Silence Therapeutics (SLN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
News Placeholder
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Given Average Recommendation of "Moderate Buy" by Brokerages
Shares of Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN - Get Free Report) have received an average recommendation of "Moderate Buy" from the seven brokerages that are presently covering the...
News Placeholder
Silence Therapeutics (NASDAQ:SLN) Rating Increased to Strong-Buy at Jefferies Financial Group
Jefferies Financial Group raised shares of Silence Therapeutics to a "strong-buy" rating in a report on Wednesday...
News Placeholder
What is HC Wainwright's Estimate for SLN FY2030 Earnings?
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN - Free Report) - Equities research analysts at HC Wainwright issued their FY2030 EPS estimates for Silence Therapeutics in a research report issued...
News Placeholder
Silence Therapeutics' (SLN) "Buy" Rating Reiterated at HC Wainwright
HC Wainwright reaffirmed a "buy" rating and issued a $75.00 price target on shares of Silence Therapeutics in a research note on Friday...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available